4578
Otsuka Holdings Co., Ltd.
大塚ホールディングス株式会社Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Price
¥11,715
Market Cap
¥6.2T
Ent. Value
¥5.8T
Net Cash
¥407.6B
Shares Out.
528.1M
P / E
17.1×
EV / EBIT
12.1×
P / Book
—
P / NCAV
11.80×
Div. Yield
1.20%
Financials
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥2,468.9B | ¥2,329.9B | ¥2,018.6B | ¥1,738.0B | ¥1,498.3B |
| Cost of Sales | ¥699.1B | ¥660.4B | ¥611.2B | ¥569.5B | ¥495.0B |
| Gross Profit | ¥1,769.8B | ¥1,669.4B | ¥1,407.3B | ¥1,168.5B | ¥1,003.2B |
| SG&A | ¥1,004.5B | ¥958.3B | ¥807.4B | ¥724.1B | ¥622.3B |
| Operating Income | ¥479.4B | ¥323.6B | ¥139.6B | ¥150.3B | ¥154.5B |
| Non-Operating Income | ¥15.7B | ¥21.1B | ¥9.6B | ¥28.7B | ¥14.0B |
| Non-Operating Expenses | ¥27.0B | ¥8.8B | ¥6.5B | ¥6.1B | ¥4.8B |
| Pre-tax Income | ¥468.0B | ¥335.9B | ¥142.7B | ¥173.0B | ¥163.6B |
| Net Income (owners) | ¥363.1B | ¥343.1B | ¥121.6B | ¥134.0B | ¥125.5B |
| Minority Interest | ¥3.1B | ¥4.2B | ¥3.9B | ¥3.4B | ¥3.7B |
| Comprehensive Income | ¥443.7B | ¥460.2B | ¥227.8B | ¥272.4B | ¥217.3B |
| EBITDA | ¥595.5B | ¥431.5B | ¥237.4B | ¥244.1B | ¥239.4B |
| EPS | ¥685.06 | ¥633.76 | ¥224.10 | ¥247.01 | ¥231.32 |
| Shares Outstanding | 528.1M | 537.1M | 542.7M | 542.6M | 542.4M |
| Shares Issued (total) | 543.0M | 552.0M | 557.8M | 557.8M | 557.8M |
| Treasury Shares | 14.9M | 14.9M | 15.1M | 15.2M | 15.4M |